SY-5933 / Shouyao Holdings - LARVOL DELTA

Targeting FAK to improve the therapy of KRAS G12C mutant cancers (AACR 2024) - "In conclusion, our results demonstrate that CT-707 has the potential to enhance the efficacy of SY-5933 by suppressing adaptive FAK activation under KRAS G12C inhibition. This provides a rationale for an innovative combination therapy to improve outcomes in patients with KRAS G12C mutated cancers."

Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS

Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation (clinicaltrials.gov) - P1/2 | N=102 | Not yet recruiting | Sponsor: Shouyao Holdings (Beijing) Co. LTD

New P1/2 trial • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • KRAS

A Phase I Study of SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: Shouyao Holdings (Beijing) Co. LTD

Metastases • New P1 trial • Oncology • Solid Tumor • KRAS